Santhera Pharmaceuticals Aktie

13,24 EUR -0,20 EUR -1,49 %

09:17:14

STU

12,58 CHF +0,10 CHF +0,80 %

28.05.2025

SWX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.173,03 Mio. EUR

Div. Rendite0,00%

WKNA3EJMQ

ISINCH1276028821

SymbolSPHDF

Santhera Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

29.06.23GlobeNewswireSanthera Publishes Timeline of the Reverse Share Split

27.06.23GlobeNewswireShareholders Approve all Board Proposals at Today’s Annual General Meeting

20.06.23GlobeNewswireSanthera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

WerbungSanthera Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

20.06.23Dow JonesPress Release: Santhera Grants Exclusive North -2-

06.06.23GlobeNewswireSanthera Publishes Agenda for its Annual General Meeting

31.05.23GlobeNewswireSanthera Publishes Annual Report 2022

27.04.23GlobeNewswireSanthera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update

25.04.23GlobeNewswireVamorolone NDA mid-cycle review meeting by FDA completed

25.04.23Dow JonesPress Release: Santhera: Vamorolone NDA mid-cycle review meeting by FDA completed

02.03.23GlobeNewswireSanthera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy

02.03.23Dow JonesPress Release: Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy

28.02.23GlobeNewswireSanthera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement

28.02.23Dow JonesPress Release: Santhera Secures Additional -2-

08.02.23Dow JonesPress Release: Santhera Concludes Agreement with French Authorities on Raxone(R) Reimbursement and Plans to Submit a Request for an Early Access Program for ...

10.01.23Dow JonesPress Release: Santhera enters into CHF 5 million share exchange agreement

09.01.23Dow JonesPress Release: Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

29.11.22Dow JonesPress Release: Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meeting

04.11.22GlobeNewswireSanthera Calls Extraordinary General Meeting to Seek Approval for Further Financings

04.11.22Dow JonesPress Release: Santhera Calls Extraordinary General Meeting to Seek Approval for Further Financings

31.10.22GlobeNewswireEuropean Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

31.10.22Dow JonesPress Release: European Medicines Agency Validates Santhera's Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

31.10.22GlobeNewswireSanthera Announces Half-Year 2022 Financial Results and Provides Corporate Update

31.10.22Dow JonesPress Release: Santhera Announces Half-Year 2022 -4-

31.10.22Dow JonesPress Release: Santhera Announces Half-Year 2022 -3-

31.10.22Dow JonesPress Release: Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update

27.10.22GlobeNewswireSanthera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

27.10.22Dow JonesPress Release: Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

10.10.22GlobeNewswireSanthera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congress

03.10.22GlobeNewswireSanthera Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy

29.09.22GlobeNewswireSanthera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of October

29.09.22Dow JonesPress Release: Santhera Announces Preliminary -2-

29.09.22Dow JonesPress Release: Santhera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of October

01.09.22GlobeNewswireJAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy

22.08.22GlobeNewswireSanthera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

30.06.22GlobeNewswireSanthera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting

29.06.22GlobeNewswireSanthera Updates on Ongoing NDA Submission for Vamorolone

29.06.22Dow JonesPress Release: Santhera Updates on Ongoing NDA Submission for Vamorolone

27.06.22GlobeNewswireSanthera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board

27.06.22Dow JonesPress Release: Santhera Nominates Thomas Meier, PhD, to Succeed Elmar Schnee as Chairman of the Board

10.06.22GlobeNewswireSanthera Reports 2021 Annual Results

Santhera Pharmaceuticals News

Santhera Pharmaceuticals News: auf dieser Seite finden Sie alle Santhera Pharmaceuticals News und Nachrichten zur Santhera Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Santhera Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Santhera Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.